Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Genmab A (GNMSF) EBT (2024 - 2025)

Historic EBT for Genmab A (GNMSF) over the last 2 years, with Q4 2025 value amounting to -$1.1 billion.

  • Genmab A's EBT fell 32224.35% to -$1.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1204.0, marking a year-over-year decrease of 9999.99%. This contributed to the annual value of $1204.0 for FY2025, which is 9999.99% down from last year.
  • Latest data reveals that Genmab A reported EBT of -$1.1 billion as of Q4 2025, which was down 32224.35% from $482.0 million recorded in Q3 2025.
  • Genmab A's 5-year EBT high stood at $517.0 million for Q4 2024, and its period low was -$1.1 billion during Q4 2025.